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Worldwide, every year ~42 million women with unintended 
pregnancies choose pregnancy termination, and nearly half of 
these procedures, ~20 million, are unsafe.[1] Self-induced pregnancy 
termination is one form of ‘unsafe’ or ‘illegal’ pregnancy termination, 
defined as the procedure of self-administering pharmaceutical pills 
or traditional herbs or using other means to terminate a pregnancy. [2] 
According to Bhattacharyya et al.,[3] self-induced terminations of 
pregnancy are often done clandestinely by untrained individuals or by 
the pregnant women themselves, so many of them go undocumented. 
For the purpose of the present study, self-induced late pregnancy 
termination was defined as self-administration of misoprostol to 
terminate pregnancy after 24 weeks’ gestation.
There are many reported methods of unsafe pregnancy 
termination, including drinking toxic fluids such as turpentine, 
bleach or concoctions mixed with livestock manure; inserting herbal 
preparations into the vagina or cervix; placing a foreign body such 
as a twig, coat hanger or chicken bone into the uterus; or placing 
inappropriate medication into the vagina or rectum.[1] Methods 
of external injury are also used, such as jumping from the top 
of stairs or a roof, or inflicting blunt trauma to the abdomen.[4] 
In South Africa (SA) a commonly used method of self-induced 
pregnancy termination is taking misoprostol tablets, which are sold 
illegally in most townships and cities.[5] Although misoprostol is not 
registered for use in pregnancy, it is a widely used and safe method of 
pregnancy termination[6,7] in a clinical setting when done according 
to evidence-based protocols. A fundamental requirement for safety 
is ascertainment of the gestational age, as the uterus becomes 
progressively more sensitive to misoprostol during pregnancy. A safe 
dose in early pregnancy (before 20 - 24 weeks) may cause uterine 
rupture later in pregnancy. Self-administration without healthcare 
provider supervision is potentially dangerous.
The incidence of self-induced pregnancy termination is high, 
especially in low-resource settings.[8] This is of great concern in view 
of the various adverse consequences associated with this practice. The 
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Background. Little is known about the outcomes of self-induced pregnancy termination after 24 weeks’ gestation, as previous studies have 
concentrated on outcomes before 24 weeks.
Objectives. To investigate the gestational age, misoprostol dosage, source of information on misoprostol, reasons for termination and 
outcomes of self-induced pregnancy termination after 24 weeks’ gestation.
Methods. A quantitative, retrospective case series observational research design was utilised. Paediatric case summaries and the Perinatal 
Problem Identification Programme were used to collect data. Cases of self-induced pregnancy termination using misoprostol after 24 weeks’ 
gestation treated at a tertiary hospital in the Eastern Cape Province, South Africa, during the period 1 July 2011 - 1 January 2012 were 
identified and included in the study. Frequencies and proportions were used to analyse data.
Results. Eighteen known cases of self-induced pregnancy termination using misoprostol after 24 weeks’ gestation were treated at the 
hospital during the 6-month study period. Misoprostol doses ranged from 400 to 1 200 µg. Birth weight was <500 g in 1 case (6%), 500 - 
1499 g in 12 (67%), 1 500 - 1 999 g in 2 (11%), >2 500 g in 1 (6%) and unknown in 1 (6%). Eleven of the babies (67%) were born alive 
and 5 (28%) were stillborn (1 further stillbirth (6%) was classified as an abortion, <500 g). One baby (6%) survived, and in 1 case (6%) the 
pregnancy continued. Eight of the 10 neonatal deaths were early and 2 were late. The major cause of neonatal death was hyaline membrane 
disease (n=8, 44%). Other causes were hypoxia (n=2), septicaemia (n=2), necrotising enterocolitis (n=2), pulmonary haemorrhage (n=2) 
and intraventricular haemorrhage (n=2). More than one cause applied in some cases. The maternal complications were manual removal of 
the placenta (n=2, 11%), ruptured uterus (n=1, 6%), and anaemia with blood transfusion (n=1, 6%).
Conclusions. Self-administration of misoprostol to induce pregnancy termination after 24 weeks’ gestation contributes to preterm births 
and perinatal morbidity and mortality. The findings of this study show that there is a need to educate women on the perinatal and maternal 
risks associated with self-induced pregnancy termination at a late stage of gestation, availability of safe options for pregnancy termination, 
and contraceptive use and adherence. Healthcare workers need to be sensitive to the possibility that cases of apparent spontaneous preterm 
labour or birth may have been self-induced.
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World Health Organization[2] has identified self-induced pregnancy 
termination as one of the preventable causes of maternal morbi dity 
and mortality. It is estimated that ~68 000 women die of self-induced 
pregnancy termination annually worldwide, making it one of the 
leading causes of maternal mortality.[1] Furthermore, Singh[8] ob served 
that ~5 million women in the developing world are hospitalised each 
year for treatment of pregnancy termination-related complications 
such as haemorrhage and sepsis, and pregnancy termination-related 
deaths leave 220 000 children motherless. Self-induced pregnancy 
termination also results in reproductive tract infections, infertility 
and a long-term risk of ectopic pregnancy, premature delivery and 
spontaneous abortion in subsequent pregnancies.[4] Common side-
effects and complications of misoprostol-induced termination of 
pregnancy include gastrointestinal side-effects, abdominal cramps, 
bleeding, fever, chills, infection and rupture of the uterus.[9]
Self-induced pregnancy termination also has economic costs: 
for example, a recent study by Benson et al.[10] estimated the costs 
of post-pregnancy termination care in the public health sector 
in Malawi at USD314 008 annually. The treatment of pregnancy 
termination-related complications may require resources such as 
blood products, antibiotics, oxytocics, anaesthesia, operating rooms 
and surgical specialists. The financial and logistical impact of treating 
complications can overwhelm the public healthcare system and 
divert limited resources from other critical healthcare programmes. 
Unmeasurable outcomes of self-induced pregnancy termination 
include loss of productivity and psychological harm.[1]
There are many reported risk factors associated with self-induced 
pregnancy termination. Empirical evidence shows that late gestational 
age, the method used, women’s readiness to seek post-pregnancy 
termination care, the quality of the facility they reach, and the 
qualifications and attitude of the healthcare provider all influence the 
risk of preterm births, perinatal morbidity and mortality, and other 
pregnancy termination-related complications.[1]
With empirical evidence that self-induced pregnancy termination 
negatively affects women, their families, the public healthcare system 
and economic productivity, it is important for countries to formulate 
strategies to prevent it. Strategies include less restrictive pregnancy 
termination laws and increased contraceptive use.[1] However, 
liberalisation of pregnancy termination laws does not guarantee the 
increased utilisation of legal pregnancy termination services. For 
example, evidence suggests that the legal pregnancy termination 
rate in SA is still low (6 per 1 000 women), and many pregnancy 
terminations are still being performed illegally, despite the enactment 
of the Choice on Termination of Pregnancy Act (Act 92 of 1996) by 
the government to promote safe pregnancy termination.[11] Although 
pregnancy termination is legal in SA, desperate women facing the 
financial burdens and social stigma of unintended pregnancy and 
believing that they have no other option continue to risk their 
lives by self-induced pregnancy termination.[1] Poor contraception 
knowledge among women, sexual violence, including rape, and 
partner opposition to pregnancy are some of the reasons women fall 
pregnant unintentionally and seek termination.[12,13] Inaccessibility 
of safe and legal pregnancy termination services and healthcare 
providers’ negative attitudes towards women seeking these services 
are reported barriers to safe pregnancy termination.[14]
Previous studies[1,8,9,15] on self-induced pregnancy termination 
using misoprostol have concentrated on outcomes before 24 weeks’ 
gestation. Little is known about the outcomes after 24 weeks.
Objectives
This study sought to fill the gap in the existing body of knowledge by 
answering the following research question: what are the gestational 
age, misoprostol dosage, source of information on misoprostol, 
reasons for self-inducing pregnancy termination, and outcomes of 
self-induced pregnancy termination after 24 weeks’ gestation?
Methods
A quantitative, retrospective case series observational research design 
was utilised. Paediatric case summaries and the Perinatal Problem 
Identification Programme were used to collect data on all known 
cases of self-induced pregnancy termination using misoprostol after 
24 weeks’ gestation treated at a tertiary hospital in the Eastern Cape 
Province, SA, during the period 1 July 2011 - 1 January 2012. Data 
were collected on demographic characteristics, gestational age at 
self-induced pregnancy termination, misoprostol dosage, reasons for 
self-inducing pregnancy termination, and outcomes. The hospital 
is a major referral health facility in the province, and performed 
11 860 deliveries during the period January 2010 - January 2011. [16] 
Purposeful sampling was used to select cases. All known cases of self-
induced pregnancy termination using misoprostol after 24  weeks’ 
gestation treated at the hospital during the study period were 
included in the study. We excluded cases of self-induced pregnancy 
termination using other methods, before 24 weeks’ gestation, not 
treated at the hospital and outside the study period. Data were 
analysed by means of frequencies and proportions. The study was 
approved by the ethics committee of the tertiary hospital (letter dated 
30 January 2012).
Results
There were 18 known cases of self-induced pregnancy termination 
using misoprostol after 24 weeks’ gestation treated at the hospital 
between 1 July 2011 and 1 January 2012.
Demographic data
The women’s ages ranged from 17 to 37 years, with a median of 26. 
Sixteen women (88%) were single, 1 (6%) was married and 1 (6%) 
Table 1. Demographic data (N=18)
Category n (%)
Age (years)
<18 1 (6)
18 - 19 2 (11)
20 - 27 7 (39)
28 - 33 7 (39)
≥34 1 (6)
Marital status
Single 16 (89)
Married 1 (6)
Widow 1 (6)
Employment status
Unemployed 10 (56)
Employed (formal) 1 (6)
Employed (informal) 2 (11)
Self-employed 1 (6)
Student/scholar 4 (22)
Parity
0 6 (33)
2 8 (44)
3 1 (6)
4 3 (17)
Previous caesarean section 7 (39)
Previous termination of pregnancy 1 (6)
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was widowed. Eight women (44%) were in their second pregnancy 
and 6  women (33%) were in their first; only 3 women (17%) and 
1 woman (6%) were in their fourth and third pregnancy, respectively. 
Of the women, 7 (39%) had had previous caesarean sections, of whom 
1 (6%) presented with abruptio placentae and 1 (6%) uterine rupture. 
One woman (6%) had had a previous termination of pregnancy. Ten 
women (56%) were unemployed, 1 (6%) had formal employment, 2 
(11%) had informal employment, 1 (6%) was self-employed and 4 
(22%) were students (Table 1).
Clinical findings, misoprostol dosage, source of 
misoprostol information and reasons for self-inducing 
pregnancy termination
Thirteen women (72%) were tested for HIV, with 7 (39%) testing 
negative and 6 (33%) positive. Four women (22%) refused HIV 
testing and 1 (6%) had unknown HIV status. Nine women (50%) 
did not book for antenatal care, 8 (44%) booked for antenatal care 
locally, and 1 (6%) booked for antenatal care 300 km away. Only 
4 women (22%) requested termination of pregnancy in the index 
pregnancy, with 3 (17%) being declined termination because they 
were over 20 weeks’ gestation, the legal maximum for termination 
of pregnancy for psychological or social indications. One woman 
(6%) was 13 - 20 weeks pregnant when she applied for termination, 
but owing to service overload there were no beds until she reached 
20 weeks (Table 2).
The gestational age at the time of taking misoprostol ranged 
from 24 to 39 weeks, with 8 women (44%) >28 weeks’ gestation. Six 
women (33%) had gestational ages ranging from 24 to 27 weeks, and 
gestational age was unknown in 4 (22%). The misoprostol dosages 
ingested ranged from 400 to 1 200 µg, with 10 women (56%) taking 
800 µg orally. Two women (11%) took 400 µg orally, 2 (11%) took 
400 µg orally and vaginally, and 1 (6%) took 1 200 µg orally. The 
misoprostol dosage was unspecified in 3 women (17%). Eleven 
women (61%) received information on misoprostol through phone 
adverts/street vendors, 1 (6%) through pamphlets in town, 1 (6%) 
through family/friend, and 1 (6%) through a general practitioner. 
The source of misoprostol information was unknown in 4 cases 
(22%). The reasons given for self-inducing pregnancy termination 
Table 2. Clinical findings, gestational age, misoprostol dosage, source of misoprostol information and reasons for self-inducing 
pregnancy termination (N=18)
Description n (%)
HIV status
Positive 6 (33)
Negative 7 (39)
Refused test 4 (22)
Not known 1 (6)
Antenatal care
Booked 8 (44)
Unbooked (casualty/general outpatient department) 9 (50)
Booked >300 km 1 (6)
Termination of pregnancy requested in current pregnancy and declined, reasons
Gestational age >20 weeks 3 (17)
13 - 20 weeks, no beds so went over gestational age for termination 1 (6)
Gestational age when misoprostol taken (weeks)
24 4 (22)
25 - 27 2 (11)
28 - 29 3 (17)
30 - 34 4 (22)
39 1 (6)
Unknown 4 (22)
Misoprostol dosage
400 µg orally 2 (11)
800 µg orally 10 (56)
400 µg vaginally and orally 2 (11)
1 200 µg orally 1 (6)
Unknown 3 (17)
Source of misoprostol information
Phoned advert/street vendor 11 (61)
Given pamphlet in town 1 (6)
Family/friend 1 (6)
General practitioner 1 (6)
Unknown 4 (22)
Reason for self-inducing pregnancy termination
Family financial pressure 8 (44)
Schooling/exams 6 (33)
New job prospect 3 (17)
Death of husband 1 (6)
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were family financial pressure in 8 cases (44%), new job prospects in 
3 (17%), wanting to go back to school or needing to write exams in 6 
(33%) and death of husband in 1 (6%) (Table 2).
Outcomes of self-induced late pregnancy termination
Ten patients (56%) presented in preterm labour (56%) and in 2 cases 
(11%) the baby was born before arrival. Other presentations were 
preterm premature rupture of membranes in 1 case (6%), abruptio 
placentae in 1 (6%), antepartum haemorrhage in 1 (6%), septic 
retained placenta in 1 (6%) and uterine rupture in 1 (6%). One 
woman (6%) failed to abort and was afraid that the baby might have 
birth defects. Antenatal steroids were given in 2 of the 11 cases in 
which the baby was born alive. The other 9 women presented in 
advanced labour or were diagnosed clinically as having an inevitable 
miscarriage although they subsequently delivered babies weighing 
>500 g.
When asked what they would do if the baby lived, 6 women (33%) 
said that they would keep the baby, 5 (28%) were unsure of what to 
do, 4 (22%) said that they would give the baby up for adoption, and 
in 3 cases there was no information. The maternal complications 
were manual removal of the placenta in 2 cases (11%), ruptured 
uterus in 1 (6%) and anaemia with blood transfusion in 1 (6%). There 
were no maternal complications in 14 cases (78%). After delivery, 
contraception was offered to 10 women (56%), with 3 (17%) refusing 
contraception, 3 (17%) opting for depot medroxyprogesterone 
acetate, 3 (17%) choosing an intrauterine contraceptive device and 1 
(6%) choosing bilateral tubal litigation. Eight women (44%) were not 
offered contraceptive counselling (Table 3).
In terms of neonatal outcomes, birth weight was <500 g in 1 (6%) 
500 - 1 499 g in 12 cases (67%), 1 500 - 1 999 g in 2 (11%), and 
>2 499  g in 1 (6%). In 1 case birth weight was unknown, and 
1  pregnancy continued. Eleven babies (61%) were born alive, 5 
(28%) were stillborn, and 1 further stillbirth (6%) was classified as a 
pregnancy termination (<500 g). Eight neonatal deaths (44%) were 
early and 2 (11%) were late. Four babies (22%) received continuous 
positive airway pressure ventilation and 5 (28%) received surfactant. 
The causes of neonatal death were hyaline membrane disease in 
8 cases (44%), hypoxia in 2 (11%), septicaemia in 2 (11%), necrotising 
enterocolitis in 2 (11%), pulmonary haemorrhage in 2 (11%) and 
intraventricular haemorrhage in 2 (11%) (Table 4). More than one 
cause applied in some cases.
Discussion
The objective of the study was to investigate the gestational 
age, misoprostol dosage, source of information on misoprostol, 
reasons for inducing pregnancy termination and outcomes of 
self-induced termination of pregnancy after 24 weeks’ gestation. 
The findings show that illegal use of misoprostol to self-induce 
pregnancy termination after 24 weeks contributes to preterm births 
and perinatal morbidity and mortality. This is a major concern 
in terms of SA’s efforts to reduce pregnancy termination-related 
mortality and morbidity. For SA, reaching the United Nations (UN) 
Sustainable Development goals of reducing the maternal mortality 
ratio to <70 per 100 000 live births, neonatal mortality to at least as 
low as 12 per 1 000 live births and under-5 mortality to at least as 
low as 25 per 1 000 live births by 2030 will be difficult if the public 
Table 3. Presentation and management, N=18
Description n (%)
Presentation
Preterm labour 10 (56)
Preterm premature rupture of membranes 1 (6)
Antepartum haemorrhage 1 (6)
Abruptio placentae* 1 (6)
Uterine rupture* 1 (6)
Baby born before arrival 2 (11)
Retained placenta 1 (6)
Pregnancy continued, fear baby would have birth defects 1 (6)
Antenatal steroids given (to 2 out of the 11 babies born alive) 2 (18)
What will mother do if baby lives?
Adoption 4 (22)
Keep baby 6 (33)
Unsure 5 (28)
Not recorded 3 (17)
Maternal complications
Anaemia with blood transfusion 1 (6)
Ruptured uterus 1 (6)
Manual removal of placenta 2 (11)
No complications 14 (78)
Contraception offered after delivery
Intrauterine contraceptive device 3 (17)
Depot medroxyprogesterone acetate 3 (17)
Refused 3 (17)
Bilateral tubal litigation 1 (6)
Not offered/discussed 8 (44)
*Both in women who had had a previous caesarean section.
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health burden of self-induced late pregnancy termination is not 
successfully addressed.[17]
Our patients’ gestational ages ranged between 24 and 39 weeks, with 
8 women (44%) >28 weeks’ gestation. Women need to be educated 
on the dangers of terminating pregnancy at late gestational ages. It is 
known that the risk of death is greater after second- than first-trimester 
pregnancy termination.[18] The further along the pregnancy is, the 
higher the mortality risk becomes. There is still difficulty in providing 
second-trimester pregnancy terminations in SA because women at this 
gestational age require admission, and the Choice on Termination of 
Pregnancy Act allows only doctors to perform the procedure.[11] The 
provision of pregnancy termination-related services at a primary care 
level is an important strategy to address this challenge. These services 
can be decentralised by the training and use of mid-level health 
providers such as midwives, nurses, clinical officers and physician 
assistants to offer pregnancy termination care.[19] Evidence from 
Nigeria shows that provision of pregnancy termination care by mid-
level health providers is effective in reducing mortality and morbidity 
due to unsafe pregnancy termination.[15]
Of 4 women (22%) who experienced maternal complications 
in this study, none died. A study by Mbele et al.[20] in the west of 
Pretoria, SA, found a large reduction in maternal mortality and no 
change in maternal morbidity due to pregnancy terminations since 
the implementation of the Choice on Termination of Pregnancy Act. 
The current study was far too small to assess maternal mortality as an 
outcome. Women with pregnancy termination should be encouraged 
to seek medical care earlier so that complications can be detected and 
managed more successfully.
Eight women (44%) in this study were not provided with post-
pregnancy termination family planning counselling. This was 
a missed opportunity. To reduce the risk of future unintended 
pregnancies, it is important to integrate post-pregnancy termination 
care and family planning services. A study by Ceylan et al.[21] has 
shown that after having a pregnancy termination, many women will 
accept contraception. A study in Zimbabwe found that contraceptive 
counselling and provision at the time of treatment reduced 
unintended pregnancies and repeat pregnancy terminations by 50% 
over 1 year compared with post-pregnancy termination patients who 
did not receive such services.[22]
In the present study the misoprostol dosages ingested ranged from 
400 to 1 200 µg, with 11 women (61%) taking ≥800 µg orally. This is 
of concern, as the misoprostol had been ingested without healthcare 
provider supervision. It has been shown that the self-administration 
of misoprostol without such supervision is not safely effective 
and could result in the need for hospitalisation.[7] A randomised 
controlled trial by Dickinson et al.[23] found that administration of 
400 µg misoprostol is more effective and associated with fewer side-
effects than dosages of >400 µg. There is a need to educate women 
on the risks associated with the use of high dosages of misoprostol to 
terminate pregnancy at a late gestational age. Misoprostol should be 
administered under the supervision of a skilled healthcare provider, 
after confirmation of the gestational age.
The reasons for self-inducing pregnancy termination given in this 
study were financial pressure in 8 cases (44%), wanting to go back 
to school or needing to write exams in 6 (33%), new job prospects 
in 3 (17%) and death of husband in 1 (6%). The unintended 
Table 4. Neonatal outcomes (N=18)
Description n (%)
Neonatal outcome
FSB 2 (11)
MSB 3 (17)
ENND 8 (44)
LNND 2 (11)
Abortion 1 (6)
Still pregnant 1 (6) 
Survived 1 (6)
Birth weight (g)
500 - 999 9 (50) (7 ENND, 1 FSB, 1 MSB)
1 000 - 1 499 3 (17) (1 ENND, 1 MSB, 1 alive)
1 500 - 1 999 2 (11) (2 LNND)
2 000 - 2 499 0
>2 499 1 (6) (FSB/BBA)
<500 1 (6) (abortion) 
Unknown weight 1 (6) (MSB)
Treatment given to babies
Continuous positive airway pressure ventilation 4 (22)
Surfactant 5 (28)
Causes of death (more than one cause in some cases)
Hyaline membrane disease 8 (44)
Necrotising enterocolitis 2 (11)
Pulmonary haemorrhage 2 (11)
Intraventricular haemorrhage 2 (11)
Hypoxia 2 (11)
Septicaemia 2 (11) 
FSB = fresh stillbirth; MSB = macerated stillbirth; ENND = early neonatal death; LNND = late neonatal death; BBA = born before arrival.
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pregnancies could have been avoided by the use of contraception. 
Women should therefore be offered contraceptive counselling and 
a choice of appropriate methods in order to reduce unintended 
pregnancies. It should be noted that 8 women in this study (44%) 
chose to self-induce pregnancy termination because of financial 
pressure. Continued gender inequality, particularly in many African 
communities, has a significant effect on prevention of unwanted 
pregnancy and women’s access to pregnancy termination-related 
care.[24] In these communities, women cannot seek medical treatment 
without the permission of their husbands, mothers-in-law or other 
family members, even if they are experiencing severe illness. This 
practice often delays women’s access to care and can lead to serious 
complications or death. Furthermore, women’s limited economic 
resources also contribute to delays in seeking services.[24] Unsafe 
pregnancy termination can therefore be prevented by increased 
autonomy so that women can make their own decisions regarding 
family planning and choice of contraceptive method.
In the present study, a woman who ingested misoprostol at 
24  weeks’ gestation failed to abort and feared that the baby would 
have birth defects. Although studies[25] have found an association 
between misoprostol exposure before 10 weeks and birth defects, 
evidence shows no clear causal relationship between later misoprostol 
exposure and birth defects, and the absolute risks of these defects 
is extremely low at 24 weeks’ gestation.[26] Women can therefore be 
reassured that there is little danger of harm to the baby after failed 
pregnancy termination at this gestational age.
In this study, women received information on misoprostol through 
informal networks such as phone adverts, street vendors, pamphlets, 
family members and friends. This is very worrying, as the misoprostol 
was self-administered without the supervision of a skilled healthcare 
provider. Although some studies[27,28] have advocated provision 
of misoprostol over the counter, as in Brazil in 1986, this would 
be hazardous in SA owing to inappropriate dosing and may be 
associated with incomplete pregnancy termination. The provision 
of misoprostol over the counter necessitates medical supervision as 
well as easy access to medical care in case of emergencies, so is not 
a viable option in SA.[28] For a successful outcome when misoprostol 
is provided over the counter, women would need to recognise 
that they are pregnant, estimate the duration of pregnancy, select 
the appropriate regimen, adhere to the correct protocol, manage 
adverse reactions and seek care if medical attention is needed, notice 
and cope with expulsion of the embryo, and recognise complete/
incomplete pregnancy termination.[27] These criteria are unlikely 
to be fulfilled in most resource-constrained societies in Africa. 
Establishment of friendly pregnancy termination care services will go 
a long way towards alleviating this problem.[29]
The major causes of neonatal death in this study were hyaline 
membrane disease in 8 cases (44%), hypoxia in 2 (11%), septicaemia 
in 2 (11%), necrotising enterocolitis in 2 (11%), pulmonary 
haemorrhage in 2 (11%) and intraventricular haemorrhage in 2 
(11%) (more than one cause applied in some cases). These findings 
concur with a study by Allanson et al.[30] on the perinatal mortality 
and associated maternal complications in an SA province that found 
the main causes of neonatal death to be immaturity (48.7%) and 
hypoxia (40.6%). Preventing self-induced pregnancy terminations 
can reduce the trauma and costs of treating preterm babies only for 
them to die later.
The present study has important implications for practice and 
research on self-induced pregnancy termination. Studies on self-
induced pregnancy termination using misoprostol have concentrated 
on perinatal outcomes before 24 weeks’ gestation.[1,8,9,15] The study 
makes an important contribution to the current body of knowledge 
concerning the outcomes of self-induced pregnancy termination after 
24 weeks.
Study limitations
The main limitations of the study are the retrospective design and 
the small sample size. As most women who self-induce pregnancy 
termination do not reveal this fact to medical services, the number 
of known cases presenting over 6 months is probably an under-
estimation of the scale of the problem. Owing to the small sample 
size, the generalisability of the findings is limited. The high-risk 
profile of patients admitted at the tertiary hospital, a referral facility 
admitting mostly high-risk patients, could also have influenced the 
findings, and there may well be other unknown factors. Although the 
interpretation of the data from this study is limited, it is possible that 
self-induced late pregnancy termination is contributing significantly 
to preterm births, perinatal morbidity and mortality. To assess the 
overall extent to which preterm births and perinatal morbidity and 
mortality rates are due to self-induced late pregnancy termination, 
further research with larger sample sizes should be conducted.
Conclusions
Self-induced late pregnancy termination using misoprostol 
contributes to preterm births and perinatal morbidity and mortality 
and poses a threat to reaching the UN Sustainable Development 
goals of reducing global maternal, neonatal and under-5 mortality 
by 2030. Women who self-induce pregnancy termination are at 
significant risk and require counselling on the perinatal risks of 
pregnancy termination at a late stage of gestation, the risk of illegal 
self-medication with misoprostol and availability of safe options 
for pregnancy termination, as well as long-term follow-up with 
counselling on contraceptive use and adherence. Health workers need 
to be sensitive to the possibility that cases of apparent spontaneous 
preterm labour or birth may have been self-induced.
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